Dana-Farber researchers described a scalable platform to discover molecular glue degraders and reported the first example of a metabolically activated molecular glue degrader. The approach is designed around redirecting an E3 ligase to degrade disease-associated proteins via the ubiquitin–proteasome system, a strategy aimed at expanding tractable targets beyond conventional binding-pocket inhibitors. The study, published in Nature, centers on a DCAF11-dependent molecular glue degrader activated by glutathionylation, supporting the concept that some molecular glues may be condition-dependent. Investigators argued that systematically expanding the E3 ligase space could broaden degrader chemotypes that can reach clinically relevant proteins. The work adds to the competitive protein-degradation landscape by focusing on discovery throughput and activation context rather than only optimizing single candidates.